missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Gibco™ Human Fractalkine (CX3CL1) Recombinant Protein, PeproTech®
Click to view available options
Cantidad:
1 mg
100 μg
20 μg
250 μg
5 μg
50 μg
500 μg
Tamaño de la unidad:
1 miligramo
100 microgramos
20 microgramos
250 microgramos
5 microgramos
50 microgramos
500 microgramos
Descripción
Recombinant Human Fractalkine is an 8.5 kDa protein containing 76 amino acid residues, including the four conserved cysteine residues present in CC chemokines. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
Chemokines are a family of proteins associated with the trafficking of leukocytes in immune surveillance and inflammatory cell recruitment. They are classified based on the positions of key cysteine residues. CX3CL1 is a CX3C chemokine known to induce adhesion and migration of leukocytes mediated by a membrane-bound and soluble form respectively. Recent experiments have shown that CX3CL1 can suppress the production of nitrous oxide, interleukin-6, and TNF-a in activated microglia and neuronal cells, suggesting that it may act as an intrinsic inhibitor against neurotoxicity by activated microglia. Its receptor, CX3CR1, also functions as a co-receptor for HIV-1 and HIV-2 envelope fusion and virus infection, which can be inhibited by CX3CL1.

Especificaciones
Especificaciones
Número de acceso | P78423 |
Para utilizar con (aplicación) | ELISA, Functional Assay, Western Blot |
Formulación | protein with no preservative |
ID de gen (Entrez) | 6376 |
Peso molecular | 8.5 kDa |
Nombre | Human Fractalkine (CX3CL1) |
Cantidad | 5 μg |
Fuente | E. coli |
Estado normativo | RUO |
Concentración de endotoxinas | <1 EU/ μg |
Mostrar más |
Corrección del contenido de un producto
Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.
Título del producto
Gibco™ Human Fractalkine (CX3CL1) Recombinant Protein, PeproTech® >
¿Detecta una oportunidad de mejora?Comparta una corrección de contenido